Agenus Inc. · NASDAQ:AGEN

Agenus — William Blair Webcast on AGEN1181 and Balstilimab AACR Presentations (April 2021)

5 slides from Agenus's conference presentation, Apr 10, 2021

Slide 1: Agenus April 2021
ogenus April 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus’ clinical development and regulatory plans and timelines, the potential for our pipeline, antici
Slide 3: AGEN1181: Unprecedented Clinical Responses in Early Phase 1
AGEN1181: Unprecedented Clinical Responses in Early Phase 1 52 patients evaluable for response at 6 weeks • Among first 21 evaluable patients treated with AGEN1181 monotherapy, 1 CR in aggressive endometrial cancer, 1 PR in melanoma • Among first 31 evaluable patients treated with AGEN1181 + balstil
Slide 4: Selective Depletion of Intratumoral Tregs
Selective Depletion of Intratumoral Tregs Subject A (AGEN1181 at 2 mg/kg Q3W): Thyroid cancer pre-treatment (Screening) CD68 CD8 FoxP3 Subject A CD8+ T-cell density Subject A Treg (CD8-/FOXP3+) cell density Screening Cycle 3 Day 1 Screening Cycle 3 Day 1 Number of CD8 positive cells per 300 15 CD8-/
Slide 5: ogenus
ogenus